# Iparomlimab and tuvonralimab

Source: https://onco.cc/drugs/iparomlimab-tuvonralimab/  
OnCo record `iparomlimab-tuvonralimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.

## Summary

Iparomlimab and tuvonralimab (QL1706) uses Qilu's MabPair platform to produce an anti-PD-1 and a short-half-life anti-CTLA-4 antibody in a single manufacturing run. The NMPA approved it in September 2024 for recurrent or metastatic cervical cancer that had failed platinum-based chemotherapy, the first dual checkpoint product approved for this cancer. Phase 3 trials in lung and liver cancers continue.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: PSB205
- Tags: china; nmpa-approved
- Code: QL1706
- Modality: Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4
- Mechanism: Two antibodies made in one cell line and given as a fixed mixture: a PD-1 blocker with a normal half-life and a CTLA-4 blocker engineered to clear quickly, so the double checkpoint blockade comes with less of the toxicity seen with ipilimumab combinations.
- Approvals: CN 2024: Recurrent or metastatic cervical cancer after platinum chemotherapy

## Sources

- ClinicalTrials.gov: trials of QL1706: https://clinicaltrials.gov/search?intr=QL1706

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- trials: [A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer](https://onco.cc/trials/nct07446387/), [A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line](https://onco.cc/trials/nct07502014/), [a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy](https://onco.cc/trials/nct06789796/), [CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C](https://onco.cc/trials/nct07383285/), [Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent](https://onco.cc/trials/nct07005583/), [Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC](https://onco.cc/trials/nct07447570/), [Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon](https://onco.cc/trials/nct07413601/), [PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC](https://onco.cc/trials/nct07416058/), [QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer](https://onco.cc/trials/nct07636226/), [QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC](https://onco.cc/trials/nct06786026/), [QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC](https://onco.cc/trials/nct06750861/), [QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06951997/), [QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer](https://onco.cc/trials/nct07110064/), [QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.](https://onco.cc/trials/nct07509515/), [QLS5132 Combination Therapy in Advanced Solid Tumors](https://onco.cc/trials/nct07453394/), [Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC](https://onco.cc/trials/nct07116577/), [Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct07150247/)

---
JSON: https://onco.cc/api/v1/entities/iparomlimab-tuvonralimab.json